Reported about 13 hours ago
Shareholders of Verona Pharma plc (VRNA) have approved a $10 billion acquisition by Merck & Co. (MRK), which will suspend trading on Nasdaq after the judicial hearing. The deal, offering $107 per share, comes as Verona Pharma reports promising results for its COPD treatment, Ohtuvayre, the first new inhaled therapy for the condition in over 20 years.
Source: YAHOO